207 related articles for article (PubMed ID: 17632584)
1. Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats.
Medeiros M; Pérez-Urizar J; Pedraza-Chaverri J; Muñoz-Arizpe R; Castañeda-Hernández G
Can J Physiol Pharmacol; 2007 May; 85(5):502-6. PubMed ID: 17632584
[TBL] [Abstract][Full Text] [Related]
2. [The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].
Liu XL; Tang J; Song J; He J; Xu P; Peng WX
Yao Xue Xue Bao; 2006 Sep; 41(9):882-7. PubMed ID: 17111838
[TBL] [Abstract][Full Text] [Related]
3. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile.
Takeda A; Horike K; Onoda H; Ohtsuka Y; Yoshida A; Uchida K; Morozumi K
Nephrology (Carlton); 2007 Apr; 12(2):197-204. PubMed ID: 17371346
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. II. In vitro release of renin, angiotensinogen and aldosterone.
Pedraza-Chaverrí J; Cruz C; Chávez MT; López A; Ibarra-Rubio ME; Tapia E; Peña JC
Rev Invest Clin; 1990; 42(2):120-6. PubMed ID: 2267444
[TBL] [Abstract][Full Text] [Related]
5. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution.
Aliabadi HM; Brocks DR; Lavasanifar A
Biomaterials; 2005 Dec; 26(35):7251-9. PubMed ID: 16005061
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome.
Xiaoli D; Qiang F
J Clin Pharmacol; 2009 Jul; 49(7):782-8. PubMed ID: 19448042
[TBL] [Abstract][Full Text] [Related]
7. A prospective cross-over study comparing the pharmacokinetics of cyclosporine A and its metabolites after oral versus short-time intravenous cyclosporine A administration in pre-heart transplant patients.
Lehle K; Kirchner GI; Rupprecht L; Gruber M; Birnbaum DE; Schmid FX; Preuner JG
Transplant Proc; 2007 Dec; 39(10):3323-8. PubMed ID: 18089380
[TBL] [Abstract][Full Text] [Related]
8. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat.
Brocks DR; Ala S; Aliabadi HM
Biopharm Drug Dispos; 2006 Jan; 27(1):7-16. PubMed ID: 16278928
[TBL] [Abstract][Full Text] [Related]
9. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A.
Song KH; Fasano A; Eddington ND
Int J Pharm; 2008 Mar; 351(1-2):8-14. PubMed ID: 17954018
[TBL] [Abstract][Full Text] [Related]
10. Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats.
Kajita T; Higashi Y; Imamura M; Maida C; Fujii Y; Yamamoto I; Miyamoto E
J Pharm Pharmacol; 2006 Jul; 58(7):997-1000. PubMed ID: 16805961
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome.
Morley TJ; Evans GO; Goodwin DA; Read NG; Hodgson ST; Hawksworth GM
Toxicol Appl Pharmacol; 1997 Oct; 146(2):299-308. PubMed ID: 9344898
[TBL] [Abstract][Full Text] [Related]
12. How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored?
Filler G
Nephrol Dial Transplant; 2005 Jun; 20(6):1032-4. PubMed ID: 15814537
[No Abstract] [Full Text] [Related]
13. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.
Hirunpanich V; Sato H
Eur J Pharm Biopharm; 2009 Oct; 73(2):247-52. PubMed ID: 19560537
[TBL] [Abstract][Full Text] [Related]
14. Effects of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats.
Balandraud-Pieri N; Queneau PE; Caroli-Bosc FX; Bertault-Pérès P; Montet AM; Durand A; Montet JC
Drug Metab Dispos; 1997 Aug; 25(8):912-6. PubMed ID: 9280397
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of drug action in disease states. XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: implications of severe hypoalbuminemia.
Hoffman A; Levy G
J Pharmacol Exp Ther; 1989 Apr; 249(1):117-22. PubMed ID: 2565385
[TBL] [Abstract][Full Text] [Related]
16. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs.
Fischer JR; Harkin KR; Freeman LC
Vet Ther; 2002; 3(4):465-73. PubMed ID: 12584684
[TBL] [Abstract][Full Text] [Related]
17. Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats.
Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
J Pharm Pharmacol; 2004 Apr; 56(4):477-83. PubMed ID: 15099443
[TBL] [Abstract][Full Text] [Related]
18. Effects of curcumin on cyclosporine-induced cholestasis and hypercholesterolemia and on cyclosporine metabolism in the rat.
Deters M; Klabunde T; Meyer H; Resch K; Kaever V
Planta Med; 2003 Apr; 69(4):337-43. PubMed ID: 12709901
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors.
Ganeval D; Fischer AM; Barre J; Pertuiset N; Dautzenberg MD; Jungers P; Houin G
Clin Nephrol; 1986 Feb; 25(2):75-80. PubMed ID: 3698349
[TBL] [Abstract][Full Text] [Related]
20. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.
Hebert MF; Townsend RW; Austin S; Balan G; Blough DK; Buell D; Keirns J; Bekersky I
J Clin Pharmacol; 2005 Aug; 45(8):954-60. PubMed ID: 16027407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
